Wyeth Premarin approval
Executive Summary
Wyeth's Premarin .3 mg and .45 mg doses approved for use in osteoporosis prevention July 16. The approval marks the fourth in recent months for lower-dose Premarin (conjugated estrogens) and Prempro (conjugated estrogens/medroxyprogesterone). The .3 mg and .45 mg Premarin hormone therapy doses were cleared by FDA for vasomotor symptoms in May 1942 and April 24, 2003, respectively. FDA recommends patients use the lowest hormone dose available; Wyeth's Premarin/Prempro website now uses the message "low is the way to go"...